Novel AMPK activators: Connexios and Boehringer ink pact

Bangalore-based biotech company Connexios Life Sciences, and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK for the treatment of patients with type-2 diabetes.

pact

Bangalore-based biotech company Connexios Life Sciences, and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK for the treatment of patients with type-2 diabetes.

The terms and financial details of the collaboration were undisclosed.

As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences' program on AMPK activators.

The program includes CNX-570 and other compounds which are in early pre-clinical development.

Boehringer Ingelheim will be responsible for all further development and commercialization of the candidates from the AMPK program.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X